STROKE/TIA IN PATIENTS WITH PATENT FORAMEN OVALE AND ENDOCARDIAL LEAD DEVICES: DO ECHOCARDIOGRAPHIC VARIABLES PREDICT OUTCOMES?  by Vaidya, Vaibhav et al.
A351
JACC April 1, 2014
Volume 63, Issue 12
Arrhythmias and Clinical EP
strokE/tia in patiEnts with patEnt foramEn oVaLE and EndocardiaL LEad dEVicEs: do 
Echocardiographic VariabLEs prEdict outcomEs?
Poster Contributions
Hall C
Saturday, March 29, 2014, 3:45 p.m.-4:30 p.m.
Session Title: Innovations in Device Management in AF: Devices
Abstract Category: 8. Arrhythmias and Clinical EP: Devices
Presentation Number: 1142-106
Authors: Vaibhav Vaidya, Amit Noheria, Christopher DeSimone, Mohammed Shahid, Charles Bruce, Naser Ammash, David Hodge, Joshua Slusser, 
Paul Friedman, Samuel Asirvatham, Mayo Clinic, Rochester, MN, USA
introduction: Patients with transvenous pacemaker or defibrillator leads and patent foramen ovale (PFO) are at an increased risk of stroke/
TIA. Echocardiographic variables such as atrial septal aneurysm (ASA), right ventricular systolic pressure (RVSP), degree of tricuspid regurgitation 
(TR) and presence of right to left shunt can conceivably increase the risk of paradoxical embolism of thrombus from the leads. We performed a 
retrospective study to determine whether these variables predict stroke/TIA among patients with PFO and endocardial leads.
methods:  We studied a cohort of 375 patients with documented PFO (on transthoracic or transesophageal echocardiography) who underwent 
pacemaker of defibrillator placement 2000 2010. We obtained information on clinical and echocardiographic variables using ICD-9 diagnosis codes 
and chart review. A vascular neurologist confirmed cryptogenic cardioembolic stroke/TIA events as outcomes. We used univariate proportional 
hazards models to assess association between echocardiographic variables and cardioembolic stroke/TIA.
results:  Mean age at device implantation was 67.7±15.5 years and 60% patients were men. 10.9% patients had stroke/TIA over 4.7 ± 3.1 
years of follow up. 250 patients had a baseline echo and 186 patients had a 1 to 6 year follow up echo. ASA was present in 9% and prominent 
Eustachian valve was present in 2% of the population. Estimated RVSP was 41.7±12.8 mm Hg at baseline and 42.1±14.1 mm Hg at follow up 
(p=0.60). Proportion of patients with a higher grade TR increased at follow up (moderate-severe TR 3% vs. 8% and severe TR 3% vs. 8%, p<0.001). 
The presence of ASA, prominent Eustachian valve, baseline RVSP, TR severity, presence of visible shunt, right-to-left or bidirectional shunt, were not 
associated with stroke/TIA (all p>0.05).
conclusions:  Among patients with transvenous device leads and a definitive diagnosis of PFO, the usual echocardiographic risk factors like ASA 
and right to left shunt are not associated with cardioembolic stroke/TIA. This suggests that presence of any intracardiac shunt or PFO in proximity of 
thrombogenic leads has the potential to cause embolic neurologic complications.
